EMEA recommends Tysabri warning update
This article was originally published in Scrip
Executive Summary
The EU'sCHMP has recommended that the product information for Elan/Biogen Idec's multiple sclerosis (MS) treatment Tysabri (natalizumab) should be updated to further increase awareness of the risk of developing progressive multifocal leukoencepthalopathy (PML) in patients taking the medicine.